RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT ID: NCT01175343
Last Updated: 2017-05-24
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
45 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-07-31
Study Completion Date
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial is studying the side effects and how well RO4929097 works in treating patients with recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00004012
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
COMPLETED
PHASE2
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096239
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
COMPLETED
PHASE2
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00096993
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
COMPLETED
PHASE2
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
NCT00093496
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
+1 more
COMPLETED
PHASE2
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00006812
Ovarian Cancer
Primary Peritoneal Cavity Cancer
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To assess the antitumor activity of RO4929097 in recurrent and / or metastatic epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer by progression free survival rate at the end of 4 cycles.
SECONDARY OBJECTIVES:
I. To assess the antitumor activity of RO4929097 through secondary endpoints including: overall response rate and CA125 response rate (GCIC criteria).
II. To assess the safety of single agent RO4929097 in advanced platinum resistant ovarian, fallopian tube and primary peritoneal cancers.
III. To explore expression of Notch biomarkers in advanced platinum resistant ovarian, fallopian, and primary peritoneal cancers.
IV. To explore the impact of RO49097 on ascitic fluid circulating tumor cells.
OUTLINE: This is a multicenter study.
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected.
After completion of study therapy, patients are followed up every month for at least 1 year.
I. To assess the antitumor activity of RO4929097 in recurrent and / or metastatic epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer by progression free survival rate at the end of 4 cycles.
SECONDARY OBJECTIVES:
I. To assess the antitumor activity of RO4929097 through secondary endpoints including: overall response rate and CA125 response rate (GCIC criteria).
II. To assess the safety of single agent RO4929097 in advanced platinum resistant ovarian, fallopian tube and primary peritoneal cancers.
III. To explore expression of Notch biomarkers in advanced platinum resistant ovarian, fallopian, and primary peritoneal cancers.
IV. To explore the impact of RO49097 on ascitic fluid circulating tumor cells.
OUTLINE: This is a multicenter study.
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected.
After completion of study therapy, patients are followed up every month for at least 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Stage IV Fallopian Tube Cancer
Stage IV Ovarian Cancer
Stage IV Primary Peritoneal Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (RO4929097)
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected.
Group Type
EXPERIMENTAL
Gamma-Secretase Inhibitor RO4929097
Intervention Type
DRUG
Given PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gamma-Secretase Inhibitor RO4929097
Given PO
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
RO4929097
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have histologically or cytologically confirmed ovarian epithelial carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma that is recurrent or metastatic; patients must have platinum resistant disease, as defined as treatment free interval less than 6 months post completion of platinum-based chemotherapy
* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral CT scan
* OR patients must have evidence of progression based on an elevated CA-125 (defined as a value of \> 2 x ULN documented on two separate determinations made \> 2 weeks apart, with the most recent being completed within 7 days prior to start of study treatment) if the physical exam is normal and maximum lesion diameter on the CT scan is \< 20 mm with conventional techniques or as \< 10 mm with spiral CT scan
* Patients must have completed any prior chemotherapy, radiotherapy or surgery \>= 4 weeks (6 weeks for nitrosoureas or mitomycin C) before study entry
* Prior radiotherapy is allowed provided that there is documented progression (either locally or systemically)
* Patients may have had up to 2 prior lines of chemotherapy for recurrent or metastatic disease
* Toxic effects from prior therapy must have resolved to grade 1 or less except for peripheral neuropathy and alopecia
* Life expectancy of greater than 12 weeks
* ECOG performance status =\< 2 (Karnofsky \>= 60%)
* Patients must have normal organ and marrow function as defined below (within 7 days prior to start of study treatment):
* Hemoglobin \>= 90 g/L
* Leukocytes \>= 3.0 x 10\^9/L
* Absolute neutrophil count \>= 1.5 x 10\^9/L
* Platelets \>= 100 x 10\^9/L
* Total bilirubin =\< 2.5 ULN (institutional upper limit of normal)
* AST (SGOT)/ALT (SGPT) =\< 1.5 x institutional upper limit of normal (=\< 5 times the ULN for patients with liver metastases)
* Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal (using Cockcroft-Gault Formula)
* All radiology studies must be performed =\< 4 weeks prior to the start of therapy
* No serious medical conditions such as myocardial infarction within 6 months prior to entry, congestive heart failure, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, psychiatric illness, or any other medical conditions that might be aggravated by treatment or limit compliance
* Currently no active, second malignancy other than non-melanoma skin cancers
* NOTE: Patients are not considered to have a "current active" malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
* The effects of RO4929097on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because Notch signal pathway inhibitors are known to cause interruption of the embryonic signaling pathway and may lead to serious or life-threatening birth defects, including brain deformities, facial malformation, heart problems, or abnormal organs; if women of childbearing potential do not abstain\* from sexual activity they must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry; women of childbearing potential can either be abstinent or use two forms of contraception for the duration of study participation and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while she is participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately
* Abstinent from sexual activity at least 4 weeks prior to study entry
* Pregnancy Testing: Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of RO4929097 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of RO4929097; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing RO4929097, the investigator or clinical staff must confirm and document the patient's use of two contraceptive methods or abstinence, dates of negative pregnancy test, and confirm the patient's understanding of the potential of RO4929097 to cause serious or life-threatening birth defects
* Female patients of childbearing potential are defined as follows:
* Patients with regular menses
* Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding
* Women who have had tubal ligation
* Female patients may be considered to NOT be of childbearing potential for the following reasons:
* The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy
* The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months
* Pre-pubertal females; the parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun; if a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward
* Ability to understand and the willingness to sign a written informed consent document
* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral CT scan
* OR patients must have evidence of progression based on an elevated CA-125 (defined as a value of \> 2 x ULN documented on two separate determinations made \> 2 weeks apart, with the most recent being completed within 7 days prior to start of study treatment) if the physical exam is normal and maximum lesion diameter on the CT scan is \< 20 mm with conventional techniques or as \< 10 mm with spiral CT scan
* Patients must have completed any prior chemotherapy, radiotherapy or surgery \>= 4 weeks (6 weeks for nitrosoureas or mitomycin C) before study entry
* Prior radiotherapy is allowed provided that there is documented progression (either locally or systemically)
* Patients may have had up to 2 prior lines of chemotherapy for recurrent or metastatic disease
* Toxic effects from prior therapy must have resolved to grade 1 or less except for peripheral neuropathy and alopecia
* Life expectancy of greater than 12 weeks
* ECOG performance status =\< 2 (Karnofsky \>= 60%)
* Patients must have normal organ and marrow function as defined below (within 7 days prior to start of study treatment):
* Hemoglobin \>= 90 g/L
* Leukocytes \>= 3.0 x 10\^9/L
* Absolute neutrophil count \>= 1.5 x 10\^9/L
* Platelets \>= 100 x 10\^9/L
* Total bilirubin =\< 2.5 ULN (institutional upper limit of normal)
* AST (SGOT)/ALT (SGPT) =\< 1.5 x institutional upper limit of normal (=\< 5 times the ULN for patients with liver metastases)
* Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal (using Cockcroft-Gault Formula)
* All radiology studies must be performed =\< 4 weeks prior to the start of therapy
* No serious medical conditions such as myocardial infarction within 6 months prior to entry, congestive heart failure, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, psychiatric illness, or any other medical conditions that might be aggravated by treatment or limit compliance
* Currently no active, second malignancy other than non-melanoma skin cancers
* NOTE: Patients are not considered to have a "current active" malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
* The effects of RO4929097on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because Notch signal pathway inhibitors are known to cause interruption of the embryonic signaling pathway and may lead to serious or life-threatening birth defects, including brain deformities, facial malformation, heart problems, or abnormal organs; if women of childbearing potential do not abstain\* from sexual activity they must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry; women of childbearing potential can either be abstinent or use two forms of contraception for the duration of study participation and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while she is participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately
* Abstinent from sexual activity at least 4 weeks prior to study entry
* Pregnancy Testing: Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of RO4929097 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of RO4929097; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing RO4929097, the investigator or clinical staff must confirm and document the patient's use of two contraceptive methods or abstinence, dates of negative pregnancy test, and confirm the patient's understanding of the potential of RO4929097 to cause serious or life-threatening birth defects
* Female patients of childbearing potential are defined as follows:
* Patients with regular menses
* Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding
* Women who have had tubal ligation
* Female patients may be considered to NOT be of childbearing potential for the following reasons:
* The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy
* The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months
* Pre-pubertal females; the parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun; if a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
* Patients may not be receiving any other investigational agents
* Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or other agents used in the study
* Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin ®) are ineligible
* Preclinical studies indicate that RO4929097 is a substrate of CYP3A4 and inducer of CYP3A4 enzyme activity; caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors; patients who are taking concurrent medications that are strong inducers, inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk; if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study
* Patients with malabsorption syndrome, bowel obstruction, or other condition that would interfere with intestinal absorption; patients must be able to swallow tablets
* Patients who are serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis are ineligible
* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study because RO4929097 is a Notch pathway inhibiting agent with the potential for serious or life-threatening birth defects or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with RO4929097, breastfeeding should be discontinued if the mother is treated with RO4929097; these potential risks may also apply to other agents used in this study
* Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with RO4929097; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
* Cardiovascular (within 7 days prior to start of study treatment): baseline QTc \> 470 msec (female), QTc \> 450 msec (male)
* History of risk factors for QT interval prolongation, including, but not limited to family or personal history of long QT syndrome, recurrent syncope without known etiology or sudden unexpected death
* History of torsade de pointes or other significant cardiac arrhythmias or the need for concomitant meds with known potential to prolong QT interval or antiarrhythmics
* Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or other agents used in the study
* Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin ®) are ineligible
* Preclinical studies indicate that RO4929097 is a substrate of CYP3A4 and inducer of CYP3A4 enzyme activity; caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors; patients who are taking concurrent medications that are strong inducers, inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk; if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study
* Patients with malabsorption syndrome, bowel obstruction, or other condition that would interfere with intestinal absorption; patients must be able to swallow tablets
* Patients who are serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis are ineligible
* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study because RO4929097 is a Notch pathway inhibiting agent with the potential for serious or life-threatening birth defects or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with RO4929097, breastfeeding should be discontinued if the mother is treated with RO4929097; these potential risks may also apply to other agents used in this study
* Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with RO4929097; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
* Cardiovascular (within 7 days prior to start of study treatment): baseline QTc \> 470 msec (female), QTc \> 450 msec (male)
* History of risk factors for QT interval prolongation, including, but not limited to family or personal history of long QT syndrome, recurrent syncope without known etiology or sudden unexpected death
* History of torsade de pointes or other significant cardiac arrhythmias or the need for concomitant meds with known potential to prolong QT interval or antiarrhythmics
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amit Oza
Role: PRINCIPAL_INVESTIGATOR
University Health Network-Princess Margaret Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tower Cancer Research Foundation
Beverly Hills, California, United States
Site Status
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Site Status
Los Angeles County-USC Medical Center
Los Angeles, California, United States
Site Status
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Site Status
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site Status
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Site Status
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Site Status
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
Site Status
London Regional Cancer Program
London, Ontario, Canada
Site Status
Credit Valley Hospital
Mississauga, Ontario, Canada
Site Status
Ottawa Hospital-Civic Campus
Ottawa, Ontario, Canada
Site Status
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-03069
Identifier Type: REGISTRY
Identifier Source: secondary_id
PHL-079
Identifier Type: OTHER
Identifier Source: secondary_id
8635
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-03069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318
COMPLETED
PHASE2
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02050009
WITHDRAWN
PHASE1
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00753480
SUSPENDED
PHASE1
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00019461
COMPLETED
PHASE2
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900560
TERMINATED
PHASE2
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
NCT00230542
COMPLETED
PHASE2
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
NCT00369954
WITHDRAWN
PHASE2
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
NCT00003523
COMPLETED
PHASE2
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411
COMPLETED
PHASE1
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04846842
UNKNOWN
PHASE2
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT03924245
TERMINATED
PHASE1
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909
COMPLETED
PHASE2
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973
ACTIVE_NOT_RECRUITING
PHASE1
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
NCT00768144
COMPLETED
PHASE2
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01039207
COMPLETED
PHASE2
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
NCT03297489
COMPLETED
EARLY_PHASE1
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02315430
COMPLETED
PHASE2
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00060359
COMPLETED
PHASE1
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096200
COMPLETED
PHASE2
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT04029909
UNKNOWN
PHASE1
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
NCT00036751
COMPLETED
PHASE2
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00087087
COMPLETED
PHASE2
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
NCT00993616
COMPLETED
PHASE2